Taken together, these subtype-specific patterns clarify why MRI is optimally suited to guide surgical de-escalation in triple-negative and HER2-positive tumors, where enhancement reliably reflects residual disease biology, while CEM plays a pivotal role in hormone receptor-positive cancers, where non-enhancing DCIS represents the principal diagnostic and surgical challenge. Here, ERBB2 is linked to ductal breast carcinoma in situ.